As the outbreak hits 3 300 cases, implementing response measures remains challenging because of the prolonged humanitarian crisis, the unstable security situation and the resistance among the population.
Ebola vaccine candidates are currently being evaluated in phase I–III clinical trials conducted in Africa, the EU and the US. An experimental vaccine has shown to be safe and protective against the Zaire strain of the Ebola virus. It was approved for “compassionate use” in the ongoing Ebola outbreak in DRC.
